Does lipoprotein(a) promote atherosclerotic cardiovascular disease and impair fibrinolysis by mimicking plasminogen?

Lipoprotein(a) [Lp(a)] is an independent, genetically determined, and causal driver of atherosclerotic cardiovascular disease (ASCVD). Its clinical impact stems from its unique dual-nature: it acts as both a highly atherogenic LDL-like particle and a potent prothrombotic agent. In older adults, while the relative risk compared to younger populations may be slightly attenuated, elevated Lp(a) remains a critical predictor of major adverse cardiovascular events (MACE) and cardiovascular death.

Clinical and effectiveness evidence

Extensive epidemiological and Mendelian randomization studies confirm the causal link between Lp(a) and ASCVD.

• Dose-Response Relationship: Meta-analyses of over 126,000 participants show that individuals in the highest third of the Lp(a) distribution face a 66% higher risk of coronary heart disease and a 10% higher risk of stroke compared to the lowest third.
• Independence: This risk remains significant even when LDL-C is well-controlled, highlighting that Lp(a) is not merely a surrogate for other lipids but a distinct pathological factor.
• Risk Enhancement: Guidelines now recognize Lp(a) as a "risk enhancer," particularly useful for refining risk assessment in individuals where traditional calculators may underestimate the threat.

Mechanistic explanations

The prothrombotic nature of Lp(a) is primarily attributed to its apo(a) component, which is a structural mimic of plasminogen.

• Structural Homology: Apo(a) shares 70–80% sequence identity with the kringle 4 domain of plasminogen. This allows it to act as a competitive antagonist.
• Fibrinolytic Interference: Apo(a) occupies lysine-binding sites on fibrin clots that are normally reserved for plasminogen. By displacing plasminogen, it inhibits its conversion to plasmin by tissue-type plasminogen activator (tPA), thereby stalling the natural breakdown of clots.
• Clot Architecture: High Lp(a) levels result in fibrin networks that are denser and composed of thinner fibers, making them physically more resistant to enzymatic lysis.
• Platelet Activation: Beyond fibrinolysis, Lp(a) is enriched with oxidized phospholipids that enhance platelet activation and aggregation, further fostering a prothrombotic environment.

Safety and clinical considerations

• Arterial vs. Venous: While the evidence for Lp(a) driving arterial thrombosis (heart attack and stroke) is robust, its role in venous thromboembolism (VTE) is less consistent, suggesting its effects are most dangerous in the high-shear environments of the arteries.
• Pharmacological Targeted: Currently, standard therapies like statins do not effectively lower Lp(a); however, newer antisense oligonucleotides and siRNA therapies specifically targeting apo(a) production are in late-stage clinical trials and show promise in significantly reducing Lp(a) levels.

Bottom line

Lipoprotein(a) is a causal driver of cardiovascular disease that promotes a prothrombotic state. It does this by mimicking plasminogen to block clot breakdown and by increasing platelet reactivity, leading to denser, more persistent clots that accelerate arterial damage.